Adverse Events Following Immunization
Cumulative no. of doses vaccinated and adverse events following immunization (AEFI) reported（up to 28 February）
CoronaVac (Sinovac)
Comirnaty (BioNTech)
Cumulative number of doses vaccinated and AEFI reported
Up to and including 28/02/2023, the Department of Health had received a total of 8104 AEFI reports, including 120 deaths, 2725 hospitalisation cases and 5259 other cases.
(a) Hospitalisation Cases reported by Hospital Authority (from 01/02/2023 to 28/02/2023)
* Severity index defined by HA:
1 = Incident occurred but no injury sustained.
2 = Minor injury.
3 = Temporary morbidity.
4 = Significant morbidity.
5 = Major permanent loss of function / disability.
X/N = Not known or Not applicable.
§ 0 cases were reported by private hospitals.
| No. of Cases# | |
|---|---|
| Deaths | 0 |
# In the same period of 2019, among people aged 30 or above, there were 365 deaths (i.e. 6.7 per 100 000 population) and 566 deaths (10.3 per 100 000 population) due to ischaemic heart diseases and diseases of heart respectively.
(b) Other Reports of AEFIs (Top Five) (from 01/02/2023 to 28/02/2023)
Based on the 1 AEFI reports associated with CoronaVac, the five most frequently reported events are:
| Description of Events | Number of Event^ |
|---|---|
| Pruritus | 1 |
| Urticaria | 1 |
| Rash | 1 |
| Allergic reaction | 1 |
| Hypersensitivity | 1 |
^ One report may have more than one event.
Based on the 7 AEFI reports associated with Comirnaty, the five most frequently reported events are:
| Description of Events | Number of Event^ |
|---|---|
| Facial weakness | 1 |
| Dizziness | 1 |
| Pain in limb | 1 |
| Shortness of breath | 1 |
| Facial palsy | 1 |
^ One report may have more than one event.
Remarks
Unless otherwise stated, figures of the day are updated every evening.
Any subsequent data amendment or update will be reflected after data synchronization on every 1st and 15th days of the month.
The population eligible for vaccination is based on provisional estimate of the year-end population for 2021 provided by the Census and Statistics Department.
The COVID-19 Vaccination Programme was officially launched on 26 February 2021.
Administration of CoronaVac (Sinovac) vaccine started on 26 February 2021.
Administration of Comirnaty (BioNTech) vaccine started on 10 March 2021 (Remark: suspended from 24 March to 4 April) .
A number of individuals received doses of the CoronaVac (Sinovac) and Comirnaty (BioNTech) vaccines during the soft launch of the COVID-19 Vaccination Programme (before official launch).
